BridgeBio Pharma Q1 revenue rises 67% on Attruby sales

BridgeBio Pharma

07/05/2026 21:16

Overview

US rare disease drugmaker's Q1 revenue rose yr/yr on strong Attruby sales and royalty growth

Company posted a Q1 net loss per share of $0.84, narrowing from $0.88 a year earlier

Board authorized a $500 mln share repurchase program

Outlook

Company anticipates U.S. launch of BBP-418 for LGMD2I/R9 in late 2026 or early 2027

BridgeBio expects to submit NDA for encaleret in ADH1 in 1H 2026, with U.S. launch in early 2027

Company plans NDA submission for infigratinib in achondroplasia in Q3 2026, U.S. launch expected early to mid 2027

Result Drivers

ATTRUBY SALES GROWTH - Q1 revenue increase was primarily driven by a $143.9 mln rise in net product revenue from Attruby, reflecting strong prescribing growth and patient persistence

BROAD ATTRUBY UPTAKE - Company cited continued broad uptake among all patient types and healthcare provider segments, with particularly strong and growing demand in treatment-naïve patients

HIGHER OPERATING COSTS - Operating expenses rose due to increased SG&A for commercialization of Attruby and pre-commercial activities for late-stage pipeline products, as well as higher R&D spending

Company press release: ID:nGNXcd3h6W

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.84
Q1 Net Income
-$166.56 mln
Q1 Operating Income
-$105.96 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BridgeBio Pharma Inc is $99.00, about 45.4% above its May 6 closing price of $68.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)